

**FHS PUBLIC ACCESS**

Author manuscript

Semin Immunol. Author manuscript; available in PMC 2018 October 01.

Published in final edited form as:

Semin Immunol. 2017 October ; 33: 37–43. doi:10.1016/j.smim.2017.08.006.

Too much of a good thing: How modulating LTB₄ actions restore host defense in homeostasis or disease

Stephanie L. Brandt^{a,b} and C. Henrique Serezani^{a,b,*}^aDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN Indiana University School of Medicine Department of Microbiology and Immunology, Indianapolis, IN. USA^bDivision of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN. USA

Abstract

The ability to regulate inflammatory pathways and host defense mechanisms is critical for maintaining homeostasis and responding to infections and tissue injury. While unbalanced inflammation is detrimental to the host; inadequate inflammation might not provide effective signals required to eliminate pathogens. On the other hand, aberrant inflammation could result in organ damage and impair host defense. The lipid mediator leukotriene B₄ (LTB₄) is a potent neutrophil chemoattractant and recently, its role as a dominant molecule that amplifies many arms of phagocyte antimicrobial effector function has been unveiled. However, excessive LTB₄ production contributes to disease severity in chronic inflammatory diseases such as diabetes and arthritis, which could potentially be involved in poor host defense in these groups of patients. In this review we discuss the cellular and molecular programs elicited during LTB₄ production and actions on innate immunity host defense mechanisms as well as potential therapeutic strategies to improve host defense.

Keywords

Leukotriene B₄; innate immunity; inflammation; host defense; immune regulation; microbicidal activity

1. Introduction

The ability of innate immune cells to properly recognize, respond, and eliminate invading pathogens is a requisite for host survival. Microbial infections quickly elicit an inflammatory program that induces the recruitment of phagocytes, such as macrophages, monocytes and neutrophils. These newly migrated cells further enhance the production of pro-inflammatory

*Address correspondence: Dr. C. Henrique Serezani, Department of Medicine, Division of Infectious Disease, Vanderbilt University School of Medicine, A2200 MCN 1161 21st Avenue South Nashville, TN 37232-2582 Phone: (615) 322-8972, Fax: (615) 322-3171. h.serezan@vanderbilt.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

mediators such as cytokines, chemokines, growth factors, and bioactive lipids in the inflammatory milieu. After exposure to pathogens, sentinel cells such as epithelial cells and phagocytes (tissue resident macrophages and dendritic cells) detect pathogen associated molecular patterns (PAMPs) via binding to pattern recognition receptors (PRRs). Activation of PRRs such as Toll like receptors (TLRs) trigger the signaling programs that culminate in the generation of inflammatory cytokines and lipid mediators to provide signals essential to the recruitment of cells involved in the control of pathogens. The bioactive lipid mediator leukotriene B₄ (LTB₄) is produced primarily by neutrophils and macrophages and signals through its high or low affinity receptor B leukotriene receptor (BLT) 1 or 2, respectively, to enhance phagocyte antimicrobial effector functions. However, aberrant levels of LTB₄ can be detrimental to host response and may be pathogenic in inflammatory diseases.

Effective inflammatory programs induced during infections can be compromised by underlying health conditions [1]. Although inflammation is important for coordinating immune responses during infection, excessive inflammatory responses can be destructive. Patients with chronic inflammatory diseases, such as diabetes, arthritis, and atherosclerosis have dysregulated inflammatory response functions and are more prone to infections [2–4].

This review covers the current understanding of the role of LTB₄ and BLT1 on host defense mechanisms and how modulating the LTB₄/BLT1 pathway can be therapeutically targeted to respectively amplify or inhibit host defense in settings of immunodeficiency or aberrant inflammation.

2. LT synthesis and receptors

2.1 LT synthesis

LTs are part of a large family of lipids termed eicosanoids that are derived from the Greek word “eicosa” since eicosanoids are made of 20 carbon atoms called eicosatetraenoic acid. The synthesis of LTs involves several rate-limiting steps that comprise activation of phospholipase A₂ (PLA₂) and arachidonic acid (AA) release from phospholipids in the cellular membranes. Activation of 5-LO in concert with the 5-LO activation protein (FLAP) metabolizes AA to LTA₄, which is converted to LTB₄ by LTA₄ hydrolase. LTA₄ could alternatively be modified with glutathione by LTC₄ synthase to form LTC₄. Further modifications of LTC₄ give rise to LTD₄ and LTE₄. Since LTC₄, D₄, and E₄ contain a cysteine, they are known as the cysteinyl leukotrienes (CysLTs). Even though CysLTs exert stimulatory effects on macrophages and neutrophils, this review will focus primarily on LTB₄ actions. The main cellular sources of LTB₄ in both murine and humans are granulocytes, monocytes, and macrophages (Table 1) [5]. However, murine (RAW264.7 and J774) and human (THP1 and U937) macrophage cell lines express low levels of 5-LO and produce barely detectable levels of LTB₄ [6]. Non-immune cells are also capable to produce LTB₄. Some cell types have been reported to express some but not all of the LT-synthesis enzymes, which renders these cells incapable of synthesizing leukotrienes independently. However, these cells may be able to contribute to the synthesis of LTs in a process known as transcellular biosynthesis [7]. An example of transcellular biosynthesis of LTB₄ is between neutrophils-erythrocytes, and keratinocytes and endothelial cells [8–12]. Table 1 lists the

cellular expression of leukotriene synthesis enzymes. Although this topic is of interest, a more comprehensive review can be found at [13].

5-LO activity is dependent on various signals including calcium release and phosphorylation, which control the catalytic site and the translocation of 5-LO within the cell. In a resting cell, 5-LO location varies depending on the cell type [14]. In neutrophils and peritoneal macrophages, 5-LO is located in the cytosol whereas in alveolar macrophages and Langerhans cells, 5-LO is located within in the nucleus [15–17]. Upon cell activation, increased intracellular calcium levels induce 5-LO to translocate to the perinuclear or plasmatic membrane where it can metabolize AA into LTA₄ [18]. 5-LO activity is triggered by various stimuli such as pathogens, cytokines, and immune complexes [19]. During infection, pathogens have limited abilities to increase intracellular calcium levels and therefore are poor 5-LO activators alone. However, treating infected cells with a calcium ionophore or opsonized zymosan particles are able to greatly enhance LT synthesis [20, 21]. Table 2 lists the relative levels of LTB₄ produced in response to various stimuli. The molecular mechanisms that regulate 5-lipoxygenase activation are reviewed here [22, 23].

2.2 LTB₄ receptors

There are two G protein coupled receptors (GPCRs) for LTB₄, BLT1 and BLT2. BLT1 is a high-affinity receptor and BLT2 is a low-affinity receptor. Since other fatty acid metabolites besides LTB₄ are able to activate BLT2, the effects of BLT2 signaling are not limited strictly to LTB₄ effects [24]. Distribution of BLT1 and BLT2 on cells and tissues vary between mouse and human [24]. On human cells, BLT1 expression is limited to leukocytes (Table 1) and BLT2 is ubiquitously found on many cell types. On mouse cells, BLT1 expression is detected on leukocytes and BLT2 is found on intestinal epithelium and keratinocytes [24, 25]. BLT1 can be coupled to G_{αi} or G_{αq} that culminate to decrease cyclic AMP (cAMP) levels and increase intracellular calcium levels, respectively [26]. We have previously shown that BLT1 utilizes mainly G_{αi} to enhance antimicrobial effector functions in alveolar macrophages [26]. Figure 1 demonstrates a schematic of LTB₄/BLT1-induced effector functions in innate immune cells. The low affinity receptor BLT2 is also expressed in phagocytes, but its role in host defense is poorly studied. Previously, we have shown blocking BLT2 does not influence phagocytosis and bacterial killing in alveolar macrophages [27]. However, BLT2 might be a relevant receptor for other antimicrobial effector functions in different organs [24]. Recently, Zhang and Brown have shown that in the absence of BLT1, BLT2 enhances macrophage *Borrelia burgdorferi* phagocytosis. It remains to be determined whether BLT2 amplifies neutrophil chemotaxis to the site of infection and whether BLT2 controls antimicrobial peptide production in the skin or in the gut. However, BLT2 regulation and actions are out of the scope of this review.

3. Effects of LTB₄ on host defense mechanisms

3.1 Migration and chemotaxis

Neutrophils are the first cells recruited to the site of infection or injury. There are various steps involved in successful recruitment of neutrophils: rolling, adhesion, and transendothelial migration [28]. LTB₄ is well known for its role as a neutrophil

chemoattractant from distant sites to the site of inflammation [29–31]. Also, LTB₄ participates with chemokine gradients to further enhance neutrophil chemotaxis towards other chemoattractants such as fMLP, C5a, and heme [32–34]. Neutrophils from mice lacking BLT1 are not able to swarm and cluster to a focal damage site. BLT1^{-/-} neutrophils have smaller neutrophil clusters than wild type neutrophils [35], demonstrating the importance of LTB₄/BLT1 signaling in neutrophil accumulation. Additionally, neutrophil recruitment is not unidirectional. Reverse transendothelial migration has been reported where neutrophils reenter the blood stream after migration to the site of infection or injury [36]. In a model of ischemia-reperfusion injury, LTB₄ and neutrophil elastase compose an important axis that drives reverse transendothelial migration. Neutrophils that reenter the vasculature are able to migrate to secondary organs and have the potential to cause injury [37].

3.2 Phagocytosis

We, and others, have shown that LTB₄/BLT1 signaling amplifies the actions of different signaling components required for ingestion of particles. The first demonstration that LTB₄ enhances phagocytosis was shown by Wirth et al using a model of *Trypanosoma cruzi* infection [38]. After this, Dr. Peters-Golden's group pioneered in demonstrating the role of endogenous LTs in amplifying phagocytosis of antibody-opsonized targets [39, 40]. Both genetic and pharmacologic blockage of LTB₄/BLT1 actions greatly reduces ingestion of a myriad of pathogens, including both gram-positive bacteria (*Streptococcus pneumoniae*) [27], gram-negative bacteria (*Klebsiella pneumoniae* [41]), fungi (*Histoplasma capsulatum* [42, 43], *Candida albicans* [44], and *Paracoccidioides brasiliensis* [45]), and parasites (*Leishmania braziliensis* [46], *L. amazonensis* [47], and *T. cruzi* [38, 48]).

In addition to this extensive list of pathogens, the molecular mechanisms involved in LTB₄-mediated amplification of phagocytosis have been studied. BLT1 signaling enhances activation of Syk, a protein tyrosine kinase, important for FcγR-mediated phagocytosis [26, 49]. When macrophages are challenged with IgG-opsonized targets, LTB₄ enhances phagocytosis of IgG-RBC in an FcγR1-dependent manner. This enhancement is attributed to the association of BLT1 with lipid raft formation and heightened signaling capabilities [50]. Furthermore, LTB₄ amplifies phagocytosis by increasing phosphorylation of kinases involved in the formation of a phagocytic cup, such as PKC-α, PKC-δ, PI3K, and ERK1/2 [51, 52]. However, the hierarchical role of these kinases in amplifying phagocytosis remains to be determined. Molecular studies regarding the signaling programs involved in the phagocytosis of nonopsonized pathogens are scarcer than opsonized targets. It has been shown that LTB₄ enhances *C. albicans* phagocytosis via activation of GαI-mediated PKC-δ and PI3K activation culminating in F-actin polymerization [53]. LT enhancement of yeast phagocytosis involves the activation of PKC and PI3K, with subsequent activation of LIM Kinase, decreased cofilin-1 activation, and ultimately, F-actin assembly [53]. Furthermore, LTB₄ enhances phagocytosis of fungi by increasing the expression of dectin-1, a main phagocytic receptor detecting fungal pathogens [42]. LTB₄-mediated dectin-1 expression is dependent on GM-CSF production and activation of the transcription factor PU.1 [44].

3.3 Pathogen killing mechanisms

We, and others, have extensively shown that LTB₄ is a potent neutrophil activator [41, 54–56]. 5-LO^{-/-} neutrophils or neutrophils treated with leukotriene synthesis inhibitors have significantly lower ingestion of serum-opsonized *K. pneumoniae* [41]. Exogenous LTB₄ treatment restores phagocytic capabilities in 5-LO deficient neutrophils [40, 45]. After phagocytosis, neutrophils kill pathogens by producing toxic components within granules that are released in a process known as neutrophil degranulation [57]. When human neutrophils are infected *in vitro* with the parasite *L. amazonensis*, endogenous and exogenous LTB₄ promotes neutrophil degranulation [47]. Also, LTB₄ induces release of myeloperoxidase [55] and elastase in neutrophils [37, 58]. LTB₄ treatment of mice infected with influenza virus induced production of antimicrobial peptides β -defensin 3 and Cramp [59], the mouse ortholog of human cathelicidin LL-37. In human neutrophils, LTB₄ induces the production of LL-37 in a dose-dependent manner [56].

Reactive oxygen and nitrogen species (ROS and RNS) production is another important antimicrobial effector function that phagocytes use to kill pathogens. LTB₄ enhances the production of NADPH oxidase-dependent ROS generation [54, 60]. We, and others, have shown that LTB₄ enhances ROS-dependent NADPH oxidase activation via phosphorylation of the cytosolic subunit p47phox. This activation is dependent on PKC- δ [54], ERK-1/2 and PI3K activation [61]. LTB₄ is part of a positive-feedback loop in human neutrophils infected with *L. amazonensis*, which is important to kill parasites [47]. Similar to neutrophils, macrophages produce a variety of different microbicidal molecules such as ROS, RNS, antimicrobial peptides, and indoleamine deoxygenase (IDO). LTB₄ is known to enhance the generation of most microbicidal molecules mentioned above. LTB₄-mediated ROS production in macrophages is dependent on PKC- δ -mediated p47phox and p40phox phosphorylation and membrane translocation in alveolar macrophages challenged with opsonized *K. pneumoniae* [52]. Furthermore, we also showed that aerosolized LTB₄ increases p47phox expression and membrane translocation during *Streptococcus pneumoniae* lung infection [62]. Additionally, our unpublished results show that macrophages from BLT1^{-/-} mice have impaired phagocytosis and killing of gram-positive methicillin-resistant *Staphylococcus aureus* (MRSA), which correlates with diminished ROS production in macrophages from the BLT1 deficient mice.

LTB₄-dependent RNS production is dependent on NF κ B and STAT1 activation [46]. LTB₄ treatment further enhances the production of nitric oxide (NO) in murine macrophages, which improves killing of different pathogens such as *L. amazonensis* and *T. cruzi* [52, 63]. It remains to be determined whether LTB₄ enhances noncanonical microbicidal effectors in macrophages such as antimicrobial peptides, tryptophan depletion (via IDO activation), GTPases, and transferrin receptor activation.

3.4 PRR activation and cytokine generation

TLRs are known to detect both PAMPs and danger associated molecular patterns (DAMPs). There are 11 TLRs in human and 13 in mouse. TLRs can be found on the cell surface of immune cells or in endosomes located within cells. The role of LTB₄ in TLR activation has been suggested [64–66]. TLR signaling induces pro-inflammatory cytokine responses [67,

68]. TLR2 is a cell surface receptor that senses peptidoglycan molecules commonly found on gram-positive bacteria and TLR9 is an endosomal receptor that detects DNA [67, 68]. LTB₄ stimulation upregulates the expression of TLR2 and TLR9 in human neutrophils [69]. Enhanced expression of TLRs could allow for neutrophils to better sense various pathogens and induce a stronger signaling cascade, which allows for a more potent immune response. Furthermore, LTB₄ is also known to amplify the actions of different PRRs. TLR activation is dependent on different adaptors such as myeloid differentiation factor 88 (MyD88) and TIR-domain-containing adapter-inducing interferon- β (TRIF). Most TLRs except TLR3 utilize MyD88, and only TLR3 and TLR4 utilize TRIF. MyD88 activation is followed by phosphorylation of downstream components such as IRAKs and TAK-1. LTB₄ enhances MyD88 expression and MyD88-dependent activation of NF κ B, which are able to intensify the signaling potential of TLRs and other PRRs [64]. The mechanisms involved in LTB₄-enhanced MyD88 expression relies on enhancing the activation of STAT1, the main transcription factor responsible for MyD88 expression [70]. BLT1 activation leads to mRNA degradation of suppressor of cytokine signaling 1 (SOCS1), the major STAT1 negative regulator, which contributes to enhanced MyD88 expression and subsequent enhancement of TLR-mediated macrophage activation [64]. Furthermore, it has been shown that LTB₄ amplifies the phosphorylation of IRAK and TAK-1 in human neutrophils [66]. In all circumstances, through TLR and PRR activation, LTB₄ amplifies the induction of cytokine production. LTB₄/BLT1 enhancement of inflammatory cytokine production has been extensively studied. LTB₄ is known to induce the cytokines GM-CSF, TNF- α , IL-6 and IL-1 β and the chemokines KC, MCP-1, CXCL1, and CXCL2 that are thought to enhance inflammatory responses [71, 72].

Another layer of immune regulation induced by LTB₄ is the expression of microRNAs (small ~22 nucleotides in length) that inhibits mRNA degradation or translation. We have shown that 5-LO deficient macrophages exhibit a decreased expression of a specific set of inflammatory microRNAs (inflammatory regulon). Among these microRNAs, we detected decreased levels of miR-155, miR-125b, and miR-146b in LT-deficient cells [73]. We have shown that these microRNAs specifically bind to *SOCS1* 3'UTR, restrict SOCS1 expression and enhance MyD88 expression [64]. Therefore, LTB₄/BLT1 axis provides very potent and pleiotropic signals by decreasing microRNA expression and allowing inflammatory programs to be elicited in macrophages.

4. Aberrant LTB₄ is detrimental to host defense

Chronic inflammatory morbidities are accompanied by aberrant LTB₄ production that is thought to negatively influence disease pathogenesis. Among the diseases that LTB₄ plays a detrimental role include type 1 and type 2 diabetes, arthritis, and atherosclerosis [74–80]. The bad reputation of LTB₄ comes from its capacity to maintain inflammatory programs in monocytes/macrophages and prolonging neutrophil recruitment to the inflammatory foci. LTB₄/BLT1 blockade is expected to dampen inflammatory responses and restore tissue homeostasis during chronic inflammation.

Besides increased production of LTB₄, chronic inflammatory diseases are often associated with co-morbidities, including the major threat of increased susceptibility to infections.

Although LTB₄ plays a beneficial role in promoting pathogen clearance, the counterintuitive effect of LTB₄ in chronic inflammatory diseases could be explained by the overwhelming inflammatory response and lack of proper phagocyte response to pathogens. Abundant LTB₄ production and detrimental host defense responses have been associated in a zebrafish model of *Mycobacterium marinum* infection. The authors showed that LTA₄ hydrolase (LTA₄H), the enzyme that converts LTA₄ to LTB₄, is an important susceptibility factor involved in *Mycobacterium* infection. Zebrafish expressing hyperactive LTA₄H are hypersusceptible to *M. marinum* infection [81]. Additionally, overexpression of LTA₄H produces high levels of LTB₄ that drive aberrant TNF α production and uncontrolled mycobacterial infections [82]. Furthermore, zebrafish expressing the enzyme that inactivates LTB₄, leukotriene B₄ dehydrogenase/prostaglandin reductase 1 (LTB₄DH/PTGR1), exhibit lower bacterial numbers than WT zebrafish. The susceptibility to infection of LTB₄DH mutant animals can be reversed with BLT1 antagonism, further implicating LTB₄ as detrimental to host defense during *Mycobacteria* infection in zebrafish [83].

Exaggerated LTB₄ is also detrimental to systemic infection (sepsis). 5-LO^{-/-} mice or pharmacological inhibition of BLT1 actions protect mice during cecum ligation and puncture (CLP). 5-LO^{-/-} and WT mice treated with a LT synthesis inhibitor have drastically lower levels of neutrophil infiltrates and lower levels of inflammatory cytokines such as IL-1 β [84]. During CLP-induced sepsis, treatment with the BLT1 antagonist U-75302 decreases lung injury [85] as evidenced by decreased neutrophil recruitment. Therapeutically regulating 5-LO products or blocking BLT1 during or after sepsis may help prevent organ injury. Aberrant LTB₄ production also renders diabetic mice more susceptible to sepsis than nondiabetic animals. We have shown that increased LTB₄ drives MyD88 expression and mediates chronic systemic inflammation in diabetic mice. Diabetic BLT1^{-/-} mice are protected from sepsis, which correlates with lower inflammatory cytokine production and decreased MyD88 expression.

Given the pleiotropic effects of LTB₄ on amplifying the actions of immune receptors by influencing intracellular programs and gene transcription in macrophage and neutrophil activation [86], exaggerated LTB₄ levels could be influencing both the actions of PRR (via increased expression of MyD88 [64, 73]), cytokine (GM-CSF, TNF- α and IL1 β [44, 64, 87]), and phagocytic receptors (FcRs and dectin receptor [50, 52]) and transcription factors (NF κ B, AP1 and PU.1 [44, 64, 73]) to elicit inflammatory programs and cause organ injury and poor host defense.

The mechanisms involved in aberrant LTB₄ production and poor systemic and localized host defense remains to be determined. However, preliminary data from our laboratory suggest that local uncontrolled LTB₄ production drives a robust production of chemokines and cytokines along with overwhelming neutrophil migration to the site of infection that releases inflammatory mediators that cause tissue damage. Furthermore, exaggerated BLT1 activation seems to impair clearance of dead cells by controlling the expression of danger signals, such as CD47 [88]. When apoptotic cells are not cleared properly, these cells become necrotic and secrete many danger associated molecular patterns (DAMPs) [89, 90]. DAMP secretion might lead to LTB₄ production which could be part of an amplification loop involved in chronic inflammation and lack of bacterial clearance observed in diabetes.

Whether these molecular events are involved in enhanced susceptibility to skin infections in people with diabetes remains to be determined and are an active research program in our laboratory.

5. Manipulating LTB₄ levels/actions as a therapeutic potential to control host defense

5.1 Enhance LTB₄ effects

There are many potential advantages to using LTB₄ in immunotherapeutic protocols, which include: (i) generation of proteins is relatively expensive, time consuming and subject to contamination with products of the vectors used to generate the protein, while lipids can be produced quickly and with a high degree of purity; (ii) because lipids exhibit are known to have a short half-life, it offers flexibility and precision in controlling localized or systemic actions; (iii) LTB₄ is safe to be administered to the human lung *in vivo*; and (iv) LTB₄ could amplify initial antimicrobial responses by enhancing pathogen recognition and phagocytosis, release of NADPH oxidase-derived ROS, and pro-inflammatory responses through MyD88 expression and activation of inflammatory transcription factors.

Treatment protocols employing exogenous LTB₄ can be greatly beneficial to patients known to exhibit attenuated LT synthesis such as in malnutrition [91], cigarette smoking [92], vitamin D deficiency [93], HIV infection [94], and bone marrow transplantation [95]. These patients are more susceptible to infection. Therefore, adding back LTB₄ to immunodeficient patients could potentially restore phagocyte response and favor appropriate host defense.

We, and others, have starting paving the way to establish treatment protocols to determine the therapeutic effects of LTB₄ in host defense. Exogenous LTB₄ treatment is able to boost effector functions in wild type mice. In a model of *Streptococcus pneumoniae* lung infections, aerosolized LTB₄ treatment was effective in restoring host defense mechanisms in 5-LO^{-/-} mice and enhancing effector functions in wild type mice [62]. Intravenous injection of LTB₄ in macaques enhances plasma levels of the antimicrobial peptide α-defensins. Plasma from the treated macaques can neutralize pathogens *ex vivo* [96]. LTB₄ treatment during influenza virus infection reduces viral titers compared to untreated mice [59]. The reduction in viral titers correlates with enhanced levels of the cathelicidin-related antimicrobial peptide (Cramp). Neutrophils are a major source of Cramp so when mice are depleted of neutrophils, exogenous LTB₄ treatment during influenza infection is unable to control viral load [59].

A potential pitfall is the fact that LTB₄ could lead to overwhelming recruitment of neutrophils, which may contribute to tissue injury. Also, the stability and safety of LTB₄ *in vivo* is a concern, but its been shown that bronchoscopy instillation of LTB₄ into the airways of normal human subjects elicited a marked influx of neutrophils. Its inhalation proved to be well tolerated and caused no adverse effects on blood pressure, pulmonary function, or bronchial responsiveness [97].

The importance of LTB₄ during infections is clear and exogenous treatment with LTB₄ may be a potential therapeutic strategy. However, high LTB₄ levels during some infections or in

chronic inflammatory diseases may need to be blunted to limit inflammation and alternative therapeutic strategies to prevent infection-mediated organ injury are necessary.

5.2 Preventing exaggerated LTB₄ actions in host defense

Overwhelming production of inflammatory mediators and reactive oxygen species are known to be detrimental to host defense in different models of infection [98–101]. Therapeutic strategies to block the actions of inflammatory mediators could also restore protective host defense. In our laboratory, we are focusing our efforts in understanding whether preventing BLT1 and/or BLT2 actions could be an important tool to control exaggerated inflammatory response and poor host defense in people with preexisting chronic inflammatory conditions, such as diabetes, obesity, asthma, rheumatoid arthritis and elderly. It is known that people with diabetes are more susceptible to numerous infections, including systemic, respiratory, and skin infections [2–4]. Indeed, both innate and adaptive immune cells from diabetics have impaired functions including poor phagocytosis and killing of pathogens [102, 103]. We have shown that macrophages from diabetic mice produce higher levels of LTB₄ than from control mice even under basal conditions [65]. Although seemingly counterintuitive, the mechanism by which people with diabetes are more susceptible to infections may operate in a similar manner to other infections where high levels of LTB₄ is detrimental to host defense [81, 83]. We detected higher levels of LTB₄ in the serum of septic and diabetic mice when compared to the levels of LTB₄ detected in septic and nondiabetic mice. Diabetic mice treated with the 5-LO inhibitor AA-861 greatly improve survival during sepsis. The increase in survival correlates with reduction in IL-1 β [65]. Since LTB₄ is able to enhance IL-1 β levels through inflammasome activation [104] and that LTB₄/BLT1 signaling enhances MyD88 and NF κ B activities [64], it is possible that LTB₄ synthesis inhibition or actions prevents overwhelming Toll-interleukin receptors, such as IL1R, IL18R1 and TLR actions prevents organ damage. Therefore, a potential therapeutic opportunity to treat sepsis in diabetic mice could rely on preventing overwhelming inflammation with a BLT1 antagonist along with antibiotics to prevent bacterial growth.

Our unpublished data also show the detrimental role of aberrant LTB₄ on host defense in diabetic mice in a model of local infection. Diabetic mice are more susceptible to MRSA skin infection than nondiabetic mice. Diabetic mice infected with MRSA have increased LTB₄ production in the skin, which correlates with uncontrolled production of inflammatory mediators and neutrophil migration. Topical treatment with a BLT1 antagonist improves skin host defense in diabetic mice, as evidenced by decreased lesion size and bacterial numbers (data not shown).

6. Conclusion

LTB₄ is a homeostatic determinant for optimal host defense in healthy individuals by driving pleiotropic actions on phagocytes that include phagocyte chemotaxis, amplifying macrophage/neutrophil antimicrobial effector functions, and production of cytokines. However, during chronic diseases characterized by aberrant LTB₄ levels, excessive LTB₄ could be responsible for impaired host defense mechanisms. In the era of antibiotic-resistant pathogens, new therapeutic strategies are critically needed. Modulating levels of LTB₄ to

either enhance or limit immune responses as appropriate is a potential strategy that could be used as a single agent or in combination with antibiotics for an added benefit. There is a great need of further research in areas of inflammation regulation under homeostatic conditions and during infections as well as understanding how chronic illnesses alter these immune responses. This will allow for the development of customized immunomodulatory therapies.

Acknowledgments

We acknowledge financial support from NIH Immunology and Infectious Diseases T32 AI060519 (SLB), R01 HL124159 (CHS), and R03 AI110990-01A1 (CHS).

Abbreviations

LT	leukotriene
PAMP	pathogen associated molecular patterns
PRR	pattern recognition receptor
AA	arachidonic acid
LO	lipoxygenase
cPLA₂	cytosolic phospholipase A ₂
FLAP	5-lipoxygenase-activating protein
cysLT	cysteinyl LT
BLT	B leukotriene receptor
cAMP	cyclic adenosine monophosphate
PKC	protein kinase C
ERK	extracellular signal-related kinase
PI3K	phosphoinositide 3-kinase
NFκB	nuclear factor kappa B
AP1	activator protein 1

References

1. Dhainaut JF, Claessens YE, Janes J, Nelson DR. Underlying disorders and their impact on the host response to infection. *Clin Infect Dis*. 2005; 41(Suppl 7):S481–9. [PubMed: 16237651]
2. Aswani SM, Chandrashekar U, Shivashankara K, Pruthvi B. Clinical profile of urinary tract infections in diabetics and non-diabetics. *Australas Med J*. 2014; 7(1):29–34. [PubMed: 24567764]
3. Lipsky BA, Tabak YP, Johannes RS, Vo L, Hyde L, Weigelt JA. Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost. *Diabetologia*. 2010; 53(5):914–23. [PubMed: 20146051]

4. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. *Indian J Endocrinol Metab.* 2012; 16(Suppl 1):S27–36. [PubMed: 22701840]
5. Werz O. 5-lipoxygenase: cellular biology and molecular pharmacology. *Curr Drug Targets Inflamm Allergy.* 2002; 1(1):23–44. [PubMed: 14561204]
6. Nolfo R, Rankin JA. U937 and THP-1 cells do not release LTB₄, LTC₄, or LTD₄ in response to A23187. *Prostaglandins.* 1990; 39(2):157–65. [PubMed: 2156322]
7. Sala A, Folco G, Murphy RC. Transcellular biosynthesis of eicosanoids. *Pharmacol Rep.* 2010; 62(3):503–10. [PubMed: 20631414]
8. McGee JE, Fitzpatrick FA. Erythrocyte-neutrophil interactions: formation of leukotriene B₄ by transcellular biosynthesis. *Proc Natl Acad Sci U S A.* 1986; 83(5):1349–53. [PubMed: 3006048]
9. Iversen L, Fogh K, Ziboh VA, Kristensen P, Schmedes A, Kragballe K. Leukotriene B₄ formation during human neutrophil keratinocyte interactions: evidence for transformation of leukotriene A₄ by putative keratinocyte leukotriene A₄ hydrolase. *J Invest Dermatol.* 1993; 100(3):293–8. [PubMed: 8382716]
10. Breton J, Woolf D, Young P, Chabot-Fletcher M. Human keratinocytes lack the components to produce leukotriene B₄. *J Invest Dermatol.* 1996; 106(1):162–7. [PubMed: 8592068]
11. Janssen-Timmen U, Vickers PJ, Wittig U, Lehmann WD, Stark HJ, Fusenig NE, Rosenbach T, Radmark O, Samuelsson B, Habenicht AJ. Expression of 5-lipoxygenase in differentiating human skin keratinocytes. *Proc Natl Acad Sci U S A.* 1995; 92(15):6966–70. [PubMed: 7624354]
12. Feinmark SJ. The role of the endothelial cell in leukotriene biosynthesis. *Am Rev Respir Dis.* 1992; 146(5 Pt 2):S51–5. [PubMed: 1443908]
13. Capra V, Rovati GE, Mangano P, Buccellati C, Murphy RC, Sala A. Transcellular biosynthesis of eicosanoid lipid mediators. *Biochim Biophys Acta.* 2015; 1851(4):377–82. [PubMed: 25218301]
14. Peters-Golden, M., Brock, TG. 5-Lipoxygenase and the Nucleus: Where, When, How, and Why?. In: Samuelsson, B.Paoletti, R.Folco, GC.Granström, E., Nicosia, S., editors. *Advances in Prostaglandin and Leukotriene Research: Basic Science and New Clinical Applications.* Springer; Netherlands, Dordrecht: 2001. p. 9-15.
15. Glover S, de Carvalho MS, Bayburt T, Jonas M, Chi E, Leslie CC, Gelb MH. Translocation of the 85-kDa phospholipase A₂ from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen. *J Biol Chem.* 1995; 270(25):15359–67. [PubMed: 7797525]
16. Peters-Golden M, McNish RW. Redistribution of 5-lipoxygenase and cytosolic phospholipase A₂ to the nuclear fraction upon macrophage activation. *Biochem Biophys Res Commun.* 1993; 196(1):147–53. [PubMed: 8216286]
17. Woods JW, Coffey MJ, Brock TG, Singer II, Peters-Golden M. 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. *J Clin Invest.* 1995; 95(5):2035–46. [PubMed: 7738170]
18. Peters-Golden M. Cell biology of the 5-lipoxygenase pathway. *Am J Respir Crit Care Med.* 1998; 157(6 Pt 2):S227–31. discussion S231–2, S247–8.
19. Peters-Golden M, Brock TG. 5-Lipoxygenase and FLAP, Prostaglandins. *Leukotrienes and Essential Fatty Acids.* 2003; 69(2–3):99–109.
20. Gosselin J, Borgeat P. Epstein-Barr virus modulates 5-lipoxygenase product synthesis in human peripheral blood mononuclear cells. *Blood.* 1997; 89(6):2122–30. [PubMed: 9058735]
21. Grone M, Scheffer J, Konig W. Modulation of leukotriene generation by invasive bacteria. *Immunology.* 1992; 77(3):400–7. [PubMed: 1335960]
22. Brock TG, Peters-Golden M. Activation and regulation of cellular eicosanoid biosynthesis. *Scientific World Journal.* 2007; 7:1273–84. [PubMed: 17767350]
23. Radmark O, Samuelsson B. 5-Lipoxygenase: mechanisms of regulation. *J Lipid Res.* 2009; 50(Suppl):S40–5. [PubMed: 18987389]
24. Yokomizo T. Two distinct leukotriene B₄ receptors, BLT₁ and BLT₂. *J Biochem.* 2015; 157(2):65–71. [PubMed: 25480980]
25. Tager AM, Luster AD. BLT₁ and BLT₂: the leukotriene B₄ receptors. *Prostaglandins Leukot Essent Fatty Acids.* 2003; 69(2–3):123–34. [PubMed: 12895595]

26. Peres CM, Aronoff DM, Serezani CH, Flamand N, Faccioli LH, Peters-Golden M. Specific leukotriene receptors couple to distinct G proteins to effect stimulation of alveolar macrophage host defense functions. *J Immunol.* 2007; 179(8):5454–61. [PubMed: 17911632]
27. Soares EM, Mason KL, Rogers LM, Serezani CH, Faccioli LH, Aronoff DM. Leukotriene B4 enhances innate immune defense against the puerperal sepsis agent *Streptococcus pyogenes*. *J Immunol.* 2013; 190(4):1614–22. [PubMed: 23325886]
28. Choi EY, Santoso S, Chavakis T. Mechanisms of neutrophil transendothelial migration. *Front Biosci (Landmark Ed).* 2009; 14:1596–605. [PubMed: 19273149]
29. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. *Science.* 1987; 237(4819):1171–6. [PubMed: 2820055]
30. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. *Nature.* 1997; 387(6633):620–4. [PubMed: 9177352]
31. Woo CH, Yoo MH, You HJ, Cho SH, Mun YC, Seong CM, Kim JH. Transepithelial migration of neutrophils in response to leukotriene B4 is mediated by a reactive oxygen species-extracellular signal-regulated kinase-linked cascade. *J Immunol.* 2003; 170(12):6273–9. [PubMed: 12794160]
32. Afonso PV, Janka-Junttila M, Lee YJ, McCann CP, Oliver CM, Aamer KA, Losert W, Cicerone MT, Parent CA. LTB4 is a signal-relay molecule during neutrophil chemotaxis. *Dev Cell.* 2012; 22(5):1079–91. [PubMed: 22542839]
33. Monteiro AP, Pinheiro CS, Luna-Gomes T, Alves LR, Maya-Monteiro CM, Porto BN, Barja-Fidalgo C, Benjamim CF, Peters-Golden M, Bandeira-Melo C, Bozza MT, Canetti C. Leukotriene B4 mediates neutrophil migration induced by heme. *J Immunol.* 2011; 186(11):6562–7. [PubMed: 21536805]
34. Allendorf DJ, Yan J, Ross GD, Hansen RD, Baran JT, Subbarao K, Wang L, Haribabu B. C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and beta-glucan. *J Immunol.* 2005; 174(11):7050–6. [PubMed: 15905548]
35. Lammermann T, Afonso PV, Angermann BR, Wang JM, Kastenmuller W, Parent CA, Germain RN. Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo. *Nature.* 2013; 498(7454):371–5. [PubMed: 23708969]
36. Hirano Y, Aziz M, Wang P. Role of reverse transendothelial migration of neutrophils in inflammation. *Biol Chem.* 2016; 397(6):497–506. [PubMed: 26872312]
37. Colom B, Bodkin JV, Beyrau M, Woodfin A, Ody C, Rourke C, Chavakis T, Brohi K, Imhof BA, Nourshargh S. Leukotriene B4-Neutrophil Elastase Axis Drives Neutrophil Reverse Transendothelial Cell Migration In Vivo. *Immunity.* 2015; 42(6):1075–86. [PubMed: 26047922]
38. Wirth JJ, Kierszenbaum F. Stimulatory effects of leukotriene B4 on macrophage association with and intracellular destruction of *Trypanosoma cruzi*. *J Immunol.* 1985; 134(3):1989–93. [PubMed: 2857187]
39. Bailie MB, Standiford TJ, Laichalk LL, Coffey MJ, Strieter R, Peters-Golden M. Leukotriene-deficient mice manifest enhanced lethality from *Klebsiella pneumoniae* in association with decreased alveolar macrophage phagocytic and bactericidal activities. *J Immunol.* 1996; 157(12):5221–4. [PubMed: 8955165]
40. Mancuso P, Standiford TJ, Marshall T, Peters-Golden M. 5-Lipoxygenase reaction products modulate alveolar macrophage phagocytosis of *Klebsiella pneumoniae*. *Infect Immun.* 1998; 66(11):5140–6. [PubMed: 9784515]
41. Mancuso P, Nana-Sinkam P, Peters-Golden M. Leukotriene B4 augments neutrophil phagocytosis of *Klebsiella pneumoniae*. *Infect Immun.* 2001; 69(4):2011–6. [PubMed: 11254552]
42. Secatto A, Rodrigues LC, Serezani CH, Ramos SG, Dias-Baruffi M, Faccioli LH, Medeiros AI. 5-Lipoxygenase deficiency impairs innate and adaptive immune responses during fungal infection. *PLoS One.* 2012; 7(3):e31701. [PubMed: 22448213]
43. Secatto A, Soares EM, Locachevic GA, Assis PA, Paula-Silva FW, Serezani CH, de Medeiros AI, Faccioli LH. The leukotriene B(4)/BLT(1) axis is a key determinant in susceptibility and resistance to histoplasmosis. *PLoS One.* 2014; 9(1):e85083. [PubMed: 24465479]

44. Serezani CH, Kane S, Collins L, Morato-Marques M, Osterholzer JJ, Peters-Golden M. Macrophage dectin-1 expression is controlled by leukotriene B4 via a GM-CSF/PU.1 axis. *J Immunol.* 2012; 189(2):906–15. [PubMed: 22696442]
45. Santos PC, Santos DA, Ribeiro LS, Fagundes CT, Paula TPde, Avila TV, Lde MBaltazar, Madeira MM, Rde CCruz, Dias AC, Machado FS, Teixeira MM, Cisalpino PS, Souza DG. The pivotal role of 5-lipoxygenase-derived LTB4 in controlling pulmonary paracoccidioidomycosis. *PLoS Negl Trop Dis.* 2013; 7(8):e2390. [PubMed: 23991239]
46. Morato CI, da Silva IA Jr, Borges AF, Dorta ML, Oliveira MA, Jancar S, Serezani CH, Ribeiro-Dias F. Essential role of leukotriene B4 on *Leishmania (Viannia) braziliensis* killing by human macrophages. *Microbes Infect.* 2014; 16(11):945–53. [PubMed: 25195516]
47. Tavares NM, Araujo-Santos T, Afonso L, Nogueira PM, Lopes UG, Soares RP, Bozza PT, Bandeira-Melo C, Borges VM, Brodskyn C. Understanding the mechanisms controlling *Leishmania amazonensis* infection in vitro: the role of LTB4 derived from human neutrophils. *J Infect Dis.* 2014; 210(4):656–66. [PubMed: 24634497]
48. Talvani A, Machado FS, Santana GC, Klein A, Barcelos L, Silva JS, Teixeira MM. Leukotriene B(4) induces nitric oxide synthesis in *Trypanosoma cruzi*-infected murine macrophages and mediates resistance to infection. *Infect Immun.* 2002; 70(8):4247–53. [PubMed: 12117933]
49. Canetti C, Hu B, Curtis JL, Peters-Golden M. Syk activation is a leukotriene B4-regulated event involved in macrophage phagocytosis of IgG-coated targets but not apoptotic cells. *Blood.* 2003; 102(5):1877–83. [PubMed: 12730109]
50. Serezani CH, Aronoff DM, Sitrin RG, Peters-Golden M. FcγRI ligation leads to a complex with BLT1 in lipid rafts that enhances rat lung macrophage antimicrobial functions. *Blood.* 2009; 114(15):3316–24. [PubMed: 19657115]
51. Campos MR, Serezani CH, Peters-Golden M, Jancar S. Differential kinase requirement for enhancement of Fcγ-mediated phagocytosis in alveolar macrophages by leukotriene B4 vs. D4. *Mol Immunol.* 2009; 46(6):1204–11. [PubMed: 19223078]
52. Serezani CH, Aronoff DM, Jancar S, Mancuso P, Peters-Golden M. Leukotrienes enhance the bactericidal activity of alveolar macrophages against *Klebsiella pneumoniae* through the activation of NADPH oxidase. *Blood.* 2005; 106(3):1067–75. [PubMed: 15718414]
53. Morato-Marques M, Campos MR, Kane S, Rangel AP, Lewis C, Ballinger MN, Kim SH, Peters-Golden M, Jancar S, Serezani CH. Leukotrienes target F-actin/cofilin-1 to enhance alveolar macrophage anti-fungal activity. *J Biol Chem.* 2011; 286(33):28902–13. [PubMed: 21715328]
54. Serezani CH, Aronoff DM, Jancar S, Peters-Golden M. Leukotriene B4 mediates p47phox phosphorylation and membrane translocation in polyunsaturated fatty acid-stimulated neutrophils. *J Leukoc Biol.* 2005; 78(4):976–84. [PubMed: 16006535]
55. Widegren H, Andersson M, Borgeat P, Flamand L, Johnston S, Greiff L. LTB4 increases nasal neutrophil activity and conditions neutrophils to exert antiviral effects. *Respir Med.* 2011; 105(7):997–1006. [PubMed: 21251805]
56. Wan M, Sabirsh A, Wetterholm A, Agerberth B, Haeggstrom JZ. Leukotriene B4 triggers release of the cathelicidin LL-37 from human neutrophils: novel lipid-peptide interactions in innate immune responses. *FASEB J.* 2007; 21(11):2897–905. [PubMed: 17446260]
57. Kobayashi Y. Neutrophil biology: an update. *EXCLI J.* 2015; 14:220–7. [PubMed: 26600743]
58. Yoshimura K, Nakagawa S, Koyama S, Kobayashi T, Homma T. Roles of neutrophil elastase and superoxide anion in leukotriene B4-induced lung injury in rabbit. *J Appl Physiol* (1985). 1994; 76(1):91–6. [PubMed: 8175552]
59. Gaudreault E, Gosselin J. Leukotriene B4 induces release of antimicrobial peptides in lungs of virally infected mice. *J Immunol.* 2008; 180(9):6211–21. [PubMed: 18424743]
60. Wymann MP, von Tscharner V, Deranleau DA, Baggiolini M. The onset of the respiratory burst in human neutrophils. Real-time studies of H2O2 formation reveal a rapid agonist-induced transduction process. *J Biol Chem.* 1987; 262(25):12048–53. [PubMed: 3040727]
61. Woo CH, You HJ, Cho SH, Eom YW, Chun JS, Yoo YJ, Kim JH. Leukotriene B(4) stimulates Rac-ERK cascade to generate reactive oxygen species that mediates chemotaxis. *J Biol Chem.* 2002; 277(10):8572–8. [PubMed: 11756405]

62. Mancuso P, Lewis C, Serezani CH, Goel D, Peters-Golden M. Intrapulmonary administration of leukotriene B4 enhances pulmonary host defense against pneumococcal pneumonia. *Infect Immun*. 2010; 78(5):2264–71. [PubMed: 20231413]
63. Serezani CH, Perrela JH, Russo M, Peters-Golden M, Jancar S. Leukotrienes Are Essential for the Control of *Leishmania amazonensis* Infection and Contribute to Strain Variation in Susceptibility. *The Journal of Immunology*. 2006; 177(5):3201–3208. [PubMed: 16920959]
64. Serezani CH, Lewis C, Jancar S, Peters-Golden M. Leukotriene B4 amplifies NF-kappaB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression. *J Clin Invest*. 2011; 121(2):671–82. [PubMed: 21206089]
65. Filgueiras LR, Brandt SL, Wang S, Wang Z, Morris DL, Evans-Molina C, Mirmira RG, Jancar S, Serezani CH. Leukotriene B4-mediated sterile inflammation promotes susceptibility to sepsis in a mouse model of type 1 diabetes. *Sci Signal*. 2015; 8(361):ra10. [PubMed: 25628460]
66. Gaudreault E, Paquet-Bouchard C, Fiola S, Le Bel M, Lacerte P, Shio MT, Olivier M, Gosselin J. TAK1 contributes to the enhanced responsiveness of LTB(4)-treated neutrophils to Toll-like receptor ligands. *Int Immunol*. 2012; 24(11):693–704. [PubMed: 22843747]
67. Dowling JK, Mansell A. Toll-like receptors: the swiss army knife of immunity and vaccine development. *Clin Transl Immunology*. 2016; 5(5):e85. [PubMed: 27350884]
68. Leifer CA, Medvedev AE. Molecular mechanisms of regulation of Toll-like receptor signaling. *J Leukoc Biol*. 2016
69. Gaudreault E, Gosselin J. Leukotriene B4 potentiates CpG signaling for enhanced cytokine secretion by human leukocytes. *J Immunol*. 2009; 183(4):2650–8. [PubMed: 19620296]
70. Croker BA, Kiu H, Nicholson SE. SOCS regulation of the JAK/STAT signalling pathway. *Semin Cell Dev Biol*. 2008; 19(4):414–22. [PubMed: 18708154]
71. Huang L, Zhao A, Wong F, Ayala JM, Struthers M, Ujjainwalla F, Wright SD, Springer MS, Evans J, Cui J. Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. *Arterioscler Thromb Vasc Biol*. 2004; 24(10):1783–8. [PubMed: 15271789]
72. Saiwai H, Ohkawa Y, Yamada H, Kumamaru H, Harada A, Okano H, Yokomizo T, Iwamoto Y, Okada S. The LTB4-BLT1 axis mediates neutrophil infiltration and secondary injury in experimental spinal cord injury. *Am J Pathol*. 2010; 176(5):2352–66. [PubMed: 20304963]
73. Wang Z, Filgueiras LR, Wang S, Serezani AP, Peters-Golden M, Jancar S, Serezani CH. Leukotriene B4 enhances the generation of proinflammatory microRNAs to promote MyD88-dependent macrophage activation. *J Immunol*. 2014; 192(5):2349–56. [PubMed: 24477912]
74. Martinez-Clemente M, Claria J, Titos E. The 5-lipoxygenase/leukotriene pathway in obesity, insulin resistance, and fatty liver disease. *Curr Opin Clin Nutr Metab Care*. 2011; 14(4):347–53. [PubMed: 21587068]
75. Soumaya K. Molecular mechanisms of insulin resistance in diabetes. *Adv Exp Med Biol*. 2012; 771:240–51. [PubMed: 23393683]
76. Spite M, Hellmann J, Tang Y, Mathis SP, Kosuri M, Bhatnagar A, Jala VR, Haribabu B. Deficiency of the leukotriene B4 receptor, BLT-1, protects against systemic insulin resistance in diet-induced obesity. *J Immunol*. 2011; 187(4):1942–9. [PubMed: 21742977]
77. Ahmadzadeh N, Shingu M, Nobunaga M, Tawara T. Relationship between leukotriene B4 and immunological parameters in rheumatoid synovial fluids. *Inflammation*. 1991; 15(6):497–503. [PubMed: 1661709]
78. Chen M, Lam BK, Kanaoka Y, Nigrovic PA, Audoly LP, Austen KF, Lee DM. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. *J Exp Med*. 2006; 203(4):837–42. [PubMed: 16567388]
79. Mathis S, Jala VR, Haribabu B. Role of leukotriene B4 receptors in rheumatoid arthritis. *Autoimmun Rev*. 2007; 7(1):12–7. [PubMed: 17967719]
80. Sanchez-Galan E, Gomez-Hernandez A, Vidal C, Martin-Ventura JL, Blanco-Colio LM, Munoz-Garcia B, Ortega L, Egido J, Tunon J. Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. *Cardiovasc Res*. 2009; 81(1):216–25. [PubMed: 18852255]

81. Tobin DM, Vary JC Jr, Ray JP, Walsh GS, Dunstan SJ, Bang ND, Hagge DA, Khadge S, King MC, Hawn TR, Moens CB, Ramakrishnan L. The *Ita4h* locus modulates susceptibility to mycobacterial infection in zebrafish and humans. *Cell*. 2010; 140(5):717–30. [PubMed: 20211140]
82. Tobin DM, Roca FJ, Oh SF, McFarland R, Vickery TW, Ray JP, Ko DC, Zou Y, Bang ND, Chau TT, Vary JC, Hawn TR, Dunstan SJ, Farrar JJ, Thwaites GE, King MC, Serhan CN, Ramakrishnan L. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. *Cell*. 2012; 148(3):434–46. [PubMed: 22304914]
83. Tobin DM, Roca FJ, Ray JP, Ko DC, Ramakrishnan L. An enzyme that inactivates the inflammatory mediator leukotriene B4 restricts mycobacterial infection. *PLoS One*. 2013; 8(7):e67828. [PubMed: 23874453]
84. Monteiro AP, Soledade E, Pinheiro CS, Dellatorre-Teixeira L, Oliveira GP, Oliveira MG, Peters-Golden M, Rocco PR, Benjamim CF, Canetti C. Pivotal role of the 5-lipoxygenase pathway in lung injury after experimental sepsis. *Am J Respir Cell Mol Biol*. 2014; 50(1):87–95. [PubMed: 23947598]
85. Li XJ, Fu HY, Yi WJ, Zhao YJ, Wang J, Li JB, Wang JF, Deng XM. Dual role of leukotriene B4 receptor type 1 in experimental sepsis. *J Surg Res*. 2015; 193(2):902–8. [PubMed: 25439504]
86. Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. Leukotrienes: underappreciated mediators of innate immune responses. *J Immunol*. 2005; 174(2):589–94. [PubMed: 15634873]
87. Peters-Golden M, Henderson WR Jr. Leukotrienes *N Engl J Med*. 2007; 357(18):1841–54. [PubMed: 17978293]
88. Kojima Y, Volkmer JP, McKenna K, Civelek M, Lusic AJ, Miller CL, Drenzo D, Nanda V, Ye J, Connolly AJ, Schadt EE, Quertermous T, Betancur P, Maegdefessel L, Matic LP, Hedin U, Weissman IL, Leeper NJ. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. *Nature*. 2016; 536(7614):86–90. [PubMed: 27437576]
89. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. *Mediators Inflamm*. 2010; 2010
90. Pittman K, Kubes P. Damage-associated molecular patterns control neutrophil recruitment. *J Innate Immun*. 2013; 5(4):315–23. [PubMed: 23486162]
91. Skerrett SJ, Henderson WR, Martin TR. Alveolar macrophage function in rats with severe protein calorie malnutrition. Arachidonic acid metabolism, cytokine release, and antimicrobial activity. *J Immunol*. 1990; 144(3):1052–61. [PubMed: 2104909]
92. Balter MS, Toews GB, Peters-Golden M. Multiple defects in arachidonate metabolism in alveolar macrophages from young asymptomatic smokers. *J Lab Clin Med*. 1989; 114(6):662–73. [PubMed: 2512364]
93. Coffey MJ, Wilcoxon SE, Phare SM, Simpson RU, Gyetko MR, Peters-Golden M. Reduced 5-lipoxygenase metabolism of arachidonic acid in macrophages from 1,25-dihydroxyvitamin D3-deficient rats. *Prostaglandins*. 1994; 48(5):313–29. [PubMed: 7855310]
94. Coffey MJ, Phare SM, George S, Peters-Golden M, Kazanjian PH. Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils. *J Clin Invest*. 1998; 102(4):663–70. [PubMed: 9710433]
95. Ballinger MN, McMillan TR, Moore BB. Eicosanoid regulation of pulmonary innate immunity post-hematopoietic stem cell transplantation. *Arch Immunol Ther Exp (Warsz)*. 2007; 55(1):1–12. [PubMed: 17221337]
96. Flamand L, Tremblay MJ, Borgeat P. Leukotriene B4 Triggers the In Vitro and In Vivo Release of Potent Antimicrobial Agents. *The Journal of Immunology*. 2007; 178(12):8036–8045. [PubMed: 17548641]
97. Martin TR, Pistorese BP, Chi EY, Goodman RB, Matthay MA. Effects of leukotriene B4 in the human lung. Recruitment of neutrophils into the alveolar spaces without a change in protein permeability. *J Clin Invest*. 1989; 84(5):1609–19. [PubMed: 2553777]
98. Puchta A, Naidoo A, Verschoor CP, Loukov D, Thevaranjan N, Mandur TS, Nguyen PS, Jordana M, Loeb M, Xing Z, Kobzik L, Larche MJ, Bowdish DM. TNF Drives Monocyte Dysfunction with Age and Results in Impaired Anti-pneumococcal Immunity. *PLoS Pathog*. 2016; 12(1):e1005368. [PubMed: 26766566]

99. Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, Ma X, Ma Y, Iadecola C, Beal MF, Nathan C, Ding A. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. *J Exp Med*. 2010; 207(1):117–28. [PubMed: 20026663]
100. Headley AS, Tolley E, Meduri GU. Infections and the inflammatory response in acute respiratory distress syndrome. *Chest*. 1997; 111(5):1306–21. [PubMed: 9149588]
101. Ng HP, Zhou Y, Song K, Hodges CA, Drumm ML, Wang G. Neutrophil-mediated phagocytic host defense defect in myeloid Cfr-inactivated mice. *PLoS One*. 2014; 9(9):e106813. [PubMed: 25184794]
102. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). *FEMS Immunol Med Microbiol*. 1999; 26(3–4):259–65. [PubMed: 10575137]
103. Lecube A, Pachon G, Petriz J, Hernandez C, Simo R. Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement. *PLoS One*. 2011; 6(8):e23366. [PubMed: 21876749]
104. Amaral FA, Costa VV, Tavares LD, Sachs D, Coelho FM, Fagundes CT, Soriani FM, Silveira TN, Cunha LD, Zamboni DS, Quesniaux V, Peres RS, Cunha TM, Cunha FQ, Ryffel B, Souza DG, Teixeira MM. NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout. *Arthritis Rheum*. 2012; 64(2):474–84. [PubMed: 21952942]

Highlights

- LTB₄ triggers signaling programs necessary for effective clearance of pathogens
- LTB₄/BLT1 signaling enhances innate and adaptive immune receptor effector functions
- LTB₄ can therapeutically boost host defense in settings of host vulnerability
- Aberrant LTB₄ levels observed in chronic inflammation is harmful to host defense
- LTB₄ synthesis/actions blockage restores host defense in chronic inflammatory diseases




Fig. 1. Host defense mechanisms enhanced by LTB₄/BLT1 axis during microbial infection
Upper panel. Upon infection, microbial recognition triggers 5-LO activation to generate LTB₄ in phagocytes. *Lower panel.* LTB₄ amplifies macrophage and neutrophil effector function by enhancing the actions of different PRRs and FcR.

Table 1

Expression of LT synthesis enzymes and LTB₄ receptors in immune and structural cells.

Cell type	5-LO	FLAP	LTA ₄ hydrolase	LTC ₄ synthase	BLT1	BLT2
Neutrophil	+++	+	+++	-/+	+	+
Monocyte/macrophage	++	+	+++	+	+	+
Dendritic cell	+	+	++	+	+	+
Mast cell	+	+	+	++	+	+
Eosinophil	+	+	+	++	+	+
Endothelial cell	-	-	+	+	+	+
Red blood cell	-	-	+	-	-	-
Keratinocyte	-/+	-	+	+	+	+

Table 2

LTB₄ generation in response to various stimuli. ND not determined.

Cell type	Cytokines/Growth factors	Bacteria	Opsonized pathogen	Fungi	Viral
Neutrophil	++	++	+++	++	++
Monocyte/macrophage	++	++	+++	++	++
Dendritic cell	+	++	ND	+	+
Mast cell	+	+	ND	+	+
Endothelial cell	±	±	±	±	±